Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia.

Abstract

PURPOSE:

To describe changes in the retinal pigment epithelium (RPE) induced by photodynamic therapy (PDT) in eyes with subfoveal choroidal neovascularization (CNV) associated with pathological myopia (PM).

METHODS:

We carried out an open-label, prospective, interventional case series including 26 patients affected by subfoveal CNV in PM who underwent PDT with a 12-month follow-up. Particular attention was paid to the detection of changes at the RPE level in the areas exposed to the laser compared with baseline conditions.

RESULTS:

The median age of the patients was 58.5 years and the median duration of symptoms was 2 weeks. A pigmentary zone was present before PDT in 20 eyes (77%), incompletely encircling the CNV in all but two of the 20 eyes. At the end of the follow-up, the CNV in all eyes was seen to be completely or incompletely encircled by a band of hyperpigmentation, which was surrounded by RPE alterations, including depigmentation in all cases and atrophic changes in 14 eyes.

CONCLUSIONS:

After PDT, alterations in the RPE develop in myopic eyes. These include accentuation of the pigmentary zone surrounding the CNV and progressive atrophic changes. Further studies are needed to correlate post-PDT RPE damage with longterm visual outcome.

• Authors: Maurizio Battaglia Parodi, Stefano Da Pozzo, Giuseppe Ravalico
• Journal: Acta ophthalmologica Scandinavica (Acta Ophthalmol Scand) Vol. 85 Issue 1 Pg. 50-4 (Feb 2007) ISSN: 1395-3907 [Print] Denmark
• PMID: 17244210 (Publication Type: Journal Article)

Chemical References

• Photosensitizing Agents
• Porphyrins
• Verteporfin

Topics

• Choroidal Neovascularization (diagnosis, drug therapy, etiology)
• Female
• Fluorescein Angiography
• Humans
• Male
• Middle Aged
• Myopia, Degenerative (complications)
• Photochemotherapy
• Photosensitizing Agents (therapeutic use)
• Pigment Epithelium of Eye (pathology)
• Porphyrins (therapeutic use)
• Prospective Studies
• Verteporfin